Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
